We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up
Read MoreHide Full Article
IDEXX Laboratories, Inc. (IDXX - Free Report) posted first-quarter 2019 earnings per share (EPS) of $1.17, reflecting a 15.8% year-over-year rise on a reported basis and 27% growth at comparable constant exchange rate (CER). The figure also surpassed the Zacks Consensus Estimate by 12.5%.
Revenues in Detail
First-quarter revenues increased 7.1% year over year (up 10% on an organic basis) to $576.1 million. The metric exceeded the Zacks Consensus Estimate by 0.8%.
IDEXX Laboratories, Inc. Price, Consensus and EPS Surprise
This upside was primarily driven by strong global gains from Companion Animal Group (CAG) Diagnostics’ recurring revenues along with the expansion of global premium instrument installed base.
Segmental Analysis
IDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry and Dairy (LPD) plus Other.In the first quarter, CAG revenues climbed 9% (up 12% organically) year over year to $508.9 million. Water segment’s revenues were up 4% from the prior-year quarter (up 8% organically) to $30.3 million. LPD revenues dipped 2% (up 4% organically) to $31.5 million. Revenues at the Other segment also slipped 2.2% on a reported basis to $5.3 million.
Margins
Gross profit in the first quarter ascended 9.4% to $331.6 million in spite of a 4.2% rise in cost of revenues to $244.5 million. Accordingly, gross margin expanded 119 basis points (bps) to 57.6%.
Sales and marketing expenses rose 6.4% to $106.6 million while general and administrative expenses slid 0.9% to $60.4 million. Additionally, research and development expenses increased 8.6% to $31.5 million. Operating margin in the quarter improved 209 bps to 23.1%.
Financial Position
IDEXX exited the first quarter of 2019 with cash and cash equivalents of $116.6 million compared with $123.8 million at the end of 2018. At the end of the first quarter, net cash provided by operating activities was $34.4 million compared with $34.9 million in the year-ago period.
2019 Outlook Updated
IDEXX reaffirmed its revenue guidance for 2019. Full-year revenues are reiterated in the range of $2,385-$2,425 million, indicating organic revenue growth of 9.5-11% (reported revenue growth of 8-9.5%).
Meanwhile, EPS projection has been raised to the $4.76-$4.88 (from the past projection of $4.66-$4.78) band, suggesting annualized growth of 16-19% at CER. The current Zacks Consensus Estimate for EPS stands at $4.69 on revenues of $2.41 billion.
Our Take
IDEXX exited the first quarter on a promising note. Solid year-over-year growth in organic revenues and a lifted EPS view for 2019 are encouraging. The top line in the quarter was driven by strong sales at the CAG business. The company witnessed sturdy gains from CAG Diagnostics recurring revenues and the global premium instrument installed base in the quarter under review.
The companion animal market fundamentals remain robust with a tremendous global runway for growth. Management’s innovative multi-modality global strategy, enabled by an enhanced commercial capability, accelerated CAG Diagnostics’ recurrent revenue growth.
Stryker delivered first-quarter 2019 EPS of $1.88, beating the Zacks Consensus Estimate by 2.2%. Meanwhile, revenues of $3.52 billion were in line with the Zacks Consensus Estimate.
Abbott reported first-quarter 2019 adjusted EPS of 63 cents, trumping the Zacks Consensus Estimate by 3.3%. Also, worldwide sales totaled $7.54 billion, above the Zacks Consensus Estimate of $7.47 billion.
CONMED posted first-quarter 2019 EPS of 57 cents, which topped the Zacks Consensus Estimate of 54 cents. Moreover, revenues of $218.4 million outpaced the consensus estimate of $213 million.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up
IDEXX Laboratories, Inc. (IDXX - Free Report) posted first-quarter 2019 earnings per share (EPS) of $1.17, reflecting a 15.8% year-over-year rise on a reported basis and 27% growth at comparable constant exchange rate (CER). The figure also surpassed the Zacks Consensus Estimate by 12.5%.
Revenues in Detail
First-quarter revenues increased 7.1% year over year (up 10% on an organic basis) to $576.1 million. The metric exceeded the Zacks Consensus Estimate by 0.8%.
IDEXX Laboratories, Inc. Price, Consensus and EPS Surprise
IDEXX Laboratories, Inc. Price, Consensus and EPS Surprise | IDEXX Laboratories, Inc. Quote
This upside was primarily driven by strong global gains from Companion Animal Group (CAG) Diagnostics’ recurring revenues along with the expansion of global premium instrument installed base.
Segmental Analysis
IDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry and Dairy (LPD) plus Other.In the first quarter, CAG revenues climbed 9% (up 12% organically) year over year to $508.9 million. Water segment’s revenues were up 4% from the prior-year quarter (up 8% organically) to $30.3 million. LPD revenues dipped 2% (up 4% organically) to $31.5 million. Revenues at the Other segment also slipped 2.2% on a reported basis to $5.3 million.
Margins
Gross profit in the first quarter ascended 9.4% to $331.6 million in spite of a 4.2% rise in cost of revenues to $244.5 million. Accordingly, gross margin expanded 119 basis points (bps) to 57.6%.
Sales and marketing expenses rose 6.4% to $106.6 million while general and administrative expenses slid 0.9% to $60.4 million. Additionally, research and development expenses increased 8.6% to $31.5 million. Operating margin in the quarter improved 209 bps to 23.1%.
Financial Position
IDEXX exited the first quarter of 2019 with cash and cash equivalents of $116.6 million compared with $123.8 million at the end of 2018. At the end of the first quarter, net cash provided by operating activities was $34.4 million compared with $34.9 million in the year-ago period.
2019 Outlook Updated
IDEXX reaffirmed its revenue guidance for 2019. Full-year revenues are reiterated in the range of $2,385-$2,425 million, indicating organic revenue growth of 9.5-11% (reported revenue growth of 8-9.5%).
Meanwhile, EPS projection has been raised to the $4.76-$4.88 (from the past projection of $4.66-$4.78) band, suggesting annualized growth of 16-19% at CER. The current Zacks Consensus Estimate for EPS stands at $4.69 on revenues of $2.41 billion.
Our Take
IDEXX exited the first quarter on a promising note. Solid year-over-year growth in organic revenues and a lifted EPS view for 2019 are encouraging. The top line in the quarter was driven by strong sales at the CAG business. The company witnessed sturdy gains from CAG Diagnostics recurring revenues and the global premium instrument installed base in the quarter under review.
The companion animal market fundamentals remain robust with a tremendous global runway for growth. Management’s innovative multi-modality global strategy, enabled by an enhanced commercial capability, accelerated CAG Diagnostics’ recurrent revenue growth.
Zacks Rank & Key Picks
IDEXX has a Zacks Rank #3 (Hold). Some better-ranked stocks boasting solid results this earnings season are Stryker Corp. (SYK - Free Report) , Abbott Laboratories (ABT - Free Report) and CONMED Corp. (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered first-quarter 2019 EPS of $1.88, beating the Zacks Consensus Estimate by 2.2%. Meanwhile, revenues of $3.52 billion were in line with the Zacks Consensus Estimate.
Abbott reported first-quarter 2019 adjusted EPS of 63 cents, trumping the Zacks Consensus Estimate by 3.3%. Also, worldwide sales totaled $7.54 billion, above the Zacks Consensus Estimate of $7.47 billion.
CONMED posted first-quarter 2019 EPS of 57 cents, which topped the Zacks Consensus Estimate of 54 cents. Moreover, revenues of $218.4 million outpaced the consensus estimate of $213 million.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>